Investor Relations
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Stock Market
NASDAQSNGX
Featured Presentation
Dr. Brian Poligone, Clinical Investigator for CTCL Phase 3 FLASH Study, Answers Questions About Patient Care and Treatment Options
IR Contacts
29 Emmons Drive
Suite B-10 Princeton, NJ 08540
Telephone: 609-538-8200
ir@soligenix.com
Subscribe For Alerts
If you would like to receive our Investor Relations updates, please sign up for email alerts.